Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05766410
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
🇨🇳Department of Oncology,National Taiwan University Hospital, Taipei, Taiwan
Letrozole in Uterine Leiomyosarcoma
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT05649956
- Locations
- 🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸Endeavor Health - Kellogg Cancer Center, Evanston, Illinois, United States
🇺🇸University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 236
- Registration Number
- NCT05638594
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 120
- Registration Number
- NCT05569811
- Locations
- 🇪🇸
Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain
🇪🇸Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸Hospital Universitario de Canarias, Tenerife, Islas Canarias, Spain
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6000
- Registration Number
- NCT05514054
- Locations
- 🇺🇸
Summit Cancer Care, PC, Savannah, Georgia, United States
🇺🇸Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
🇺🇸Staten Island University Hospital, Staten Island, New York, United States
Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 194
- Registration Number
- NCT05487092
- Locations
- 🇭🇰
Kwong Wah Hospital, Hong Kong, Hong Kong
🇭🇰Princess Margaret Hospital, Hong Kong, Hong Kong
🇭🇰Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Oana Danciu
- Target Recruit Count
- 200
- Registration Number
- NCT05467891
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Phoenix, Arizona, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 40
- Registration Number
- NCT05464810
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 21
- Registration Number
- NCT05447910
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.